Intarcia Therapeutics

Intarcia Therapeutics, Inc. is a biopharmaceutical company that is committed to developing innovative therapies by using a proprietary delivery system and medicines that have the potential to change the prevention and management of severe chronic diseases.

Intarcia comprises of entrepreneurial and talented people who collaborate and achieve meaningful results. Its innovative technology platform, the Medici Drug Delivery System™, is being developed with almost two decades of visionary collaboration between a group of scientists and entrepreneurs.

Intarcia is developing its Medici Drug Delivery System™, bridging technology and medicine, to transform the treatment and prevention of chronic disease.

Intarcia’s pre-clinical candidate, ITCA 650/12M, is used for the treatment of type 2 diabetes. Exenatide, the active agent of ITCA 650/12M, is a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) is presently being developed for the treatment of T2D by delivering annual dosing of exenatide via the Medici System.

Intarcia is working to develop once-yearly anti-HIV prophylactic therapy for delivery via the Medici System through a collaboration with the Bill & Melinda Gates Foundation, and the goal is to help prevent the spread of HIV in Sub-Saharan Africa and other regions that are impacted by the HIV epidemic.